Hydroxyzine for Acute Anxiety in Bereavement
For short-term management of acute anxiety associated with bereavement, hydroxyzine 50 mg daily (divided as 12.5 mg morning and midday, 25 mg evening) can be used for up to 4 weeks maximum, but should be avoided in elderly patients and those with cardiac risk factors due to QT prolongation concerns.
Dosing Recommendations
The FDA-approved and research-validated dosing is 50 mg daily, typically divided as:
This divided dosing pattern minimizes daytime sedation while providing evening anxiolysis. Some studies used 25-100 mg at bedtime for sleep-related anxiety 3, but the 50 mg divided regimen showed superior efficacy in controlled trials 4, 2, 5.
Start with a test dose at the lower end, particularly if daytime functioning is critical, as initial sedation is common but typically resolves after the first week 5.
Duration of Treatment
Maximum 4 weeks of continuous use. The FDA label explicitly states: "The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies" 1.
Research trials demonstrating efficacy were 4 weeks 5 to 12 weeks 4 in duration. For acute bereavement-related anxiety, a 2-4 week bridge is appropriate while arranging definitive treatment (psychotherapy, SSRIs if GAD develops).
Importantly, hydroxyzine can be stopped abruptly without rebound anxiety or withdrawal symptoms 5, unlike benzodiazepines—a significant advantage for short-term use.
Critical Precautions and Contraindications
QT Prolongation Risk (Most Important Safety Concern)
Avoid or use extreme caution in patients with:
- Pre-existing heart disease
- Recent myocardial infarction
- Uncompensated heart failure
- Bradyarrhythmias
- Congenital long QT syndrome or family history
- Electrolyte imbalances (hypokalemia, hypomagnesemia)
- Concomitant QT-prolonging medications 1
The FDA label specifically warns about post-marketing cases of QT prolongation and Torsade de Pointes 1. This is particularly relevant in bereavement, as grieving patients may have poor nutrition/hydration affecting electrolytes.
Avoid combining with: SSRIs (especially citalopram), antipsychotics (ziprasidone, quetiapine), macrolide antibiotics (azithromycin, clarithromycin), or methadone 1.
Elderly Patients
Exercise extreme caution or avoid in elderly patients. The FDA label states: "Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely" 1.
Start at 25 mg daily (or less) if used in elderly, though alternative agents are generally preferred given fall risk and cognitive impairment potential.
CNS Depression
Reduce doses of concomitant CNS depressants by 50% including:
- Opioids (common in post-surgical bereavement scenarios)
- Benzodiazepines
- Barbiturates
- Alcohol 1
Warn patients explicitly about additive sedation and prohibit driving or operating machinery, especially during the first week when drowsiness peaks 5.
Acute Generalized Exanthematous Pustulosis (AGEP)
Rare but serious: Discontinue immediately if fever with pustular rash develops. Do not rechallenge. Avoid cetirizine/levocetirizine subsequently due to cross-reactivity 1.
Efficacy Evidence
Hydroxyzine demonstrated superiority over placebo in multiple RCTs for generalized anxiety:
- Significant anxiety reduction from week 1 through week 12 4, 5
- Response rates: 60-70% vs 40-50% with placebo 4
- Equivalent efficacy to benzodiazepines and buspirone 4, 2
- Targets cognitive symptoms of anxiety preferentially 6
However, a 2010 Cochrane review noted high risk of bias in included studies and concluded evidence was insufficient to recommend hydroxyzine as first-line treatment 7. This positions it appropriately as a short-term bridge rather than primary treatment.
Common Pitfalls to Avoid
Prescribing beyond 4 weeks without reassessment—no long-term safety/efficacy data 1
Ignoring cardiac screening—obtain baseline ECG in patients >50 years or with any cardiac history before prescribing 1
Using in elderly without dose reduction—standard 50 mg dose causes excessive sedation and fall risk 1
Combining with multiple CNS depressants without dose adjustment—synergistic sedation risk 1
Expecting immediate anxiolysis—peak effect occurs at 1 week, though some benefit appears within days 5
Using as monotherapy for complicated grief—hydroxyzine is a bridge; arrange psychotherapy or consider SSRIs if anxiety persists beyond 4 weeks 8
Monitoring Parameters
- Week 1: Assess sedation tolerance, functional impairment
- Week 2-4: Evaluate anxiety response, arrange definitive treatment
- Throughout: Monitor for rash, cardiac symptoms (palpitations, syncope)
- Elderly patients: Assess for confusion, falls, urinary retention
The most common adverse effect is drowsiness (28% vs 14% placebo), which typically resolves after week 1 5. Dry mouth (14%) and weight gain (12%) are also reported 5.